FDA peptide compounding plan would reportedly require purity and identity certification and adverse-event reporting

Summary. Bloomberg News reported on 22 October 2026, citing people familiar with the matter, that the FDA peptide compounding proposal under White House review includes more patient protections than initially expected. Medicaid Monitor, summarizing a Becker's Hospital Review account of that report, wrote that the plan would set temporary enforcement priorities letting compounding pharmacies make certain peptides without FDA targeting them, provided they certify the substances' purity and identity and report serious adverse events. FDA and HHS have not confirmed these details, and the notice itself, "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94), has not been published; reginfo.gov still listed it as pending review on 26 October.

Research context (RUO). According to the same summary, the plan would not formally approve the peptides as safe and effective, adverse-event reporting would be a new requirement for traditional 503A compounders, an alternative under discussion would have FDA recommend against adding certain peptides to the 503A bulks list, and any final policy would go through public comment. The reported conditions resemble safeguards that outside groups have asked for. In an August letter to FDA, the Alliance for Pharmacy Compounding (APC), a pharmacy trade group, proposed that pharmacies obtain peptide active ingredient only through FDA-registered repackagers or resellers that have validated the vendor and the manufacturer's certificate of analysis (COA) and that supply lot-specific documentation of provenance, together with serious adverse-event reporting through FDA's MedWatch program. APC reported that on 21 October a U.S. senator wrote to FDA asking for interim enforcement discretion conditioned on active ingredient from FDA-registered, CGMP-compliant facilities, prescriptions for identified patients and ongoing review of safety data. RAPS's weekly FDA roundup of 23 October also noted the opposing citizen petition from the Partnership for Safe Medicines. The background is unchanged: FDA's advisory committee voted in July to recommend six of the seven peptides it reviewed, against the advice of FDA's own reviewers; that is a recommendation, and no FDA notice listing six peptides exists. In documentation terms, "purity and identity" are the two core results on a lot-level COA: identity confirms that the material is the stated molecule, and purity reports the share of the main component, ideally alongside the impurity profile. A COA describes one lot, so its lot number, test methods, testing laboratory and date are what tie the results to a specific batch. Under current law, FDA's 503A page already requires every bulk drug substance a 503A compounder uses to be accompanied by a valid certificate of analysis and made by an FDA-registered establishment. Until the notice text is published, its scope, the substances it covers and its conditions remain unknown.

Related: FDA Peptide Compounding Policy Tracker 2026, a sourced status page for the interim notice, the July advisory votes and the 503A bulks list.

This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.

BioLabs Research has no affiliation with, and no endorsement from, any person named.